AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2015 • Lantheus Medical Imaging, Inc. • In vitro & in vivo diagnostic substances • New York
This EMPLOYMENT AGREEMENT (the “Agreement”) effective as of March 16, 2015 by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”) and Mary Anne Heino (“Executive”) supersedes and replaces in entirety the prior agreement, which was effective as of August 12, 2013.
MANUFACTURING AND SUPPLY AGREEMENT [DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension]Manufacturing and Supply Agreement • September 27th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
This Manufacturing and Supply Agreement (this “Agreement”), dated as of February 1, 2012 (the “Effective Date”), is hereby entered into by and between Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862 (“LMI”), and Jubilant HollisterStier LLC, a limited liability company organized and existing under the laws of Delaware with a place of business at 3525 North Regal Street, Spokane, Washington, 99207 (“HSL”). LMI and HSL are referred to herein individually as a “Party” and collectively as the “Parties”.
LANTHEUS MEDICAL IMAGING, INC. $150,000,000 9.750% of Senior Notes due 2017 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 21st, 2011 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”), is issuing and selling to the several initial purchasers listed in Schedule I hereto (the “Initial Purchasers”), upon the terms set forth in the Purchase Agreement, dated March 16, 2011, by and among Lantheus Medical Imaging, Inc., the Initial Purchasers and the Guarantors named therein (the “Purchase Agreement”), $150,000,000 in aggregate principal amount of 9.750% Senior Notes due 2017 issued by the Company (the “Notes”) pursuant to the Indenture (as described below). As an inducement to the Initial Purchasers to enter into the Purchase Agreement, the Company and the Guarantors listed in the signature pages hereto agree with the Initial Purchasers, for the benefit of the Holders (as defined below) of the Notes (including, without limitation, the Initial Purchasers), as follows:
AMENDMENT NUMBER ONE TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • November 12th, 2014 • Lantheus Medical Imaging, Inc. • In vitro & in vivo diagnostic substances
THIS AMENDMENT NUMBER ONE TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of June 24, 2014, is entered into by and among LANTHEUS MI INTERMEDIATE, INC., a Delaware corporation (the “Parent”), LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), the lenders identified on the signature pages hereof (such lenders, and the other lenders party to the below-defined Credit Agreement, together with their respective successors and permitted assigns, each individually, a “Lender”, and collectively, the “Lenders”), each subsidiary of the Parent listed as a “Guarantor” on the signature pages hereto (together with the Parent, each a “Guarantor” and individually and collectively, jointly and severally, the “Guarantors”; Borrower and Guarantors, each a “Loan Party” and individually and collectively, jointly and severally, the “Loan Parties”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, in its capacity as collateral agent for th
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENT (the “Agreement”) dated March 10, 2008 by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”) and Michael Duffy (“Executive”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL...Transition Services Agreement • September 27th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
This Manufacturing and Service Contract for Commercial Products (hereinafter this “Agreement”) is entered into as of March 20, 2012 (the “Effective Date”), by Ben Venue Laboratories, Inc., a corporation organized and existing under the laws of Delaware, with its principal office at 300 Northfield Road, Bedford, Ohio, 44146 (hereinafter “BVL” and as further defined in Article I) and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862 (hereinafter “Customer”). BVL and Customer may be referred to in this Agreement jointly as the “Parties” or individually as a “Party.”
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. SETTLEMENT AND...Settlement and Mutual Release Agreement • September 27th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
THIS SETTLEMENT AND MUTUAL RELEASE AGREEMENT (“Settlement Agreement”) is entered into as of the date of signature of the last signatory to the Settlement Agreement (the “Signing Date”), and effective upon the date of receipt of the Settlement Payment (as defined below) (the “Effective Date”), by and between Ben Venue Laboratories, Inc. (“BVL”), and Lantheus Medical Imaging, Inc. (“LMI”). BVL and LMI are collectively referred to as the “Parties” or in the singular as a “Party.”
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL...Transition Services Agreement • May 15th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
This Transition Services Agreement (hereinafter this “Agreement”) is made effective as of March 20, 2012 (the “Effective Date”), by Ben Venue Laboratories, Inc., a corporation organized and existing under the laws of Delaware, with its principal office at 300 Northfield Road, Bedford, Ohio, 44146 (hereinafter “BVL” and as further defined in Article I) and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware, with its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862 (hereinafter “Customer”). BVL and Customer may be referred to in this Agreement jointly as the “Parties” or individually as a “Party.”
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.Lantheus Medical Imaging, Inc. • March 29th, 2013 • Pharmaceutical preparations
Reference is made to a Molybdenum-99 Purchase & Supply Agreement dated as of April 1, 2010 (as amended by Amendment No. 1, effective as of December 1, 2010, collectively, the “Agreement”) between Lantheus Medical Imaging, Inc. and Nordion (Canada) Inc. (formerly MDS (Canada) Inc.). Terms defined in the Agreement and not otherwise defined herein are used herein with the meanings so defined.
AMENDMENT NO. 3 TO CREDIT AGREEMENTCredit Agreement • October 16th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 3, dated as of October 11, 2012 (this “Amendment”), to the Credit Agreement dated as of May 10, 2010 (as amended pursuant to that certain Amendment No. 1 to Credit Agreement, dated as of March 21, 2011, that certain Amendment No. 2 to Credit Agreement, dated as of January 26, 2012, and as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (“Borrower”), LANTHEUS MI INTERMEDIATE, INC. (“Lantheus MI”) and LANTHEUS MI REAL ESTATE, LLC (“Lantheus Real Estate” and together with Lantheus MI, the “Guarantors”), Bank of Montreal, as administrative agent (in such capacity, the “Administrative Agent”), Harris N.A., as collateral agent (in such capacity, the “Collateral Agent”), the Lenders from time to time party thereto and the other parties thereto.
LANTHEUS MI HOLDINGS, INC. 2013 EQUITY INCENTIVE PLAN NON-EMPLOYEE DIRECTOR OPTION GRANT AWARD AGREEMENTJoinder Agreement • May 6th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT (this “Agreement”) is made as of [·], 2013 (the “Grant Date”), between Lantheus MI Holdings, Inc., a Delaware corporation (the “Company”), and [Name of Director], who is a director of the Company (the “Grantee”). Capitalized terms, unless defined in Section 9 or a prior section of this Agreement, shall have the same meanings as in the Lantheus MI Holdings, Inc. 2013 Equity Incentive Plan (the “Plan”).
CONTACTS:Lantheus Medical Imaging, Inc. • January 3rd, 2013 • Pharmaceutical preparations
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.Lantheus Medical Imaging, Inc. • November 14th, 2011 • Pharmaceutical preparations
Reference is made to a Manufacturing and Supply Agreement dated as of April 6, 2009 (the “Agreement”) between Mallinckrodt Inc. and Lantheus Medical Imaging, Inc and Amended as of August 2, 2010 (“Amendment No. 1”). Terms defined in the Agreement and not otherwise defined herein are used herein with the meanings so defined.
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. Amendment No. 2...Sales Agreement • May 13th, 2011 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO SALES AGREEMENT (this “Amendment”) is made effective as of April 1, 2011 by and between NTP Radioisotopes (Pty) Ltd., a commercial company registered and existing under the laws of the Republic of South Africa, having its registered office at Building 1700, Pelindaba, Church Street West Extension, Brits District, North West Province of South Africa (“NTP”), and Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 331 Treble Cove Road, North Billerica, Massachusetts, United States of America 01862 (“Lantheus”).
December 7, 2011 PERSONAL AND CONFIDENTIAL Mr. Robert Gaffey Belmont, MA 02478 Re: Continued Services and General Release Dear Bob,Incentive Plan Option Grant Award Agreement • March 30th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Massachusetts
This letter is intended to summarize the terms of your service with Lantheus Medical Imaging, Inc. (the “Company”) as a consultant following your retirement as an employee of the Company on the Transition Date (as defined below). Please read this agreement and general release (this “Agreement”) carefully. If you agree to its terms, please sign in the space provided below and return it to me on or before January 21, 2012 as provided in Section 5.c. below.
CONFIDENTIAL SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASEConfidential Separation and Consulting Agreement and General Release • March 29th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations
THIS CONFIDENTIAL SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE (“Agreement”), dated as of February 19, 2013, is made and entered into by and between Donald Kiepert (“Executive,” “You” or “Your”) and Lantheus Medical Imaging, Inc. (defined herein to include its affiliates, subsidiaries, parents, predecessors, successors and assigns, and hereinafter referred to as “Lantheus” or the “Company”) (together, the “Parties”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 1...License and Supply Agreement • May 15th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 (this “Amendment”) to the Amended and Restated Cardiolite License and Supply Agreement by and between Lantheus Medical Imaging, Inc. (“LMI”) and Cardinal Health 414, LLC (“Licensee”) entered into as of January 1, 2009 and effective as of January 1, 2004 (the “Agreement”) is made by and between LMI and Licensee as of this 9th day of February 2012 (“Amendment Date”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. FISSIONMO-99...Confidential Treatment Requested • May 10th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations
The INSTITUT NATIONAL DES RADIOELEMENTS, a Public Utility Foundation under the laws of Belgium, located Avenue de l’Espérance, B-6220 Fleurus, Belgium (“IRE”)
AMENDMENT NO. 5 TO CREDIT AGREEMENTCredit Agreement • March 29th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 5, dated as of March 25, 2013 (this “Amendment”), to the Credit Agreement dated as of May 10, 2010 (as amended pursuant to that certain Amendment No. 1 to Credit Agreement, dated as of March 21, 2011, that certain Amendment No. 2 to Credit Agreement, dated as of January 26, 2012, that certain Amendment No. 3 to Credit Agreement, dated as of October 11, 2012, that certain Amendment No. 4 to Credit Agreement, dated as of February 28, 2013, and as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (“Borrower”), LANTHEUS MI INTERMEDIATE, INC. (“Lantheus MI”) and LANTHEUS MI REAL ESTATE, LLC (“Lantheus Real Estate” and together with Lantheus MI, the “Guarantors”), BANK OF MONTREAL, as administrative agent (in such capacity, the “Administrative Agent”), HARRIS N.A., as collateral agent (in such capacity, the “Collateral Agent”), the Lenders f
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION.Lantheus Medical Imaging, Inc. • March 8th, 2011 • Pharmaceutical preparations
Reference is made to a Molybdenum-99 Purchase & Supply Agreement dated as of April 1, 2010 (the “Agreement”) between Lantheus Medical Imaging, Inc. and Nordion (Canada) Inc. (formerly MDS (Canada) Inc.). Terms defined in the Agreement and not otherwise defined herein are used herein with the meanings so defined.
AMENDMENT NO. 2 TO CREDIT AGREEMENTCredit Agreement • January 30th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 2, dated as of January 26, 2012 (this “Amendment”), to the Credit Agreement dated as of May 10, 2010 (as amended pursuant to that certain Amendment No. 1 dated as of March 21, 2011 and as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (“Borrower”), LANTHEUS MI INTERMEDIATE, INC. (“Lantheus MI”) and LANTHEUS MI REAL ESTATE, LLC (“Lantheus Real Estate” and together with Lantheus MI, the “Guarantors”), Bank of Montreal, as administrative agent (in such capacity, the “Administrative Agent”), Harris N.A., as collateral agent (in such capacity, the “Collateral Agent”), the Lenders from time to time party thereto and the other parties thereto.
EMPLOYMENT AGREEMENTEmployment Agreement • November 12th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on this 8th day of May, 2013, by and between Lantheus Medical Imaging, Inc., and its predecessors, successors and assigns (the “Company”), and Jeffrey Bailey (“Executive”).
AMENDMENT NO. 1 TO CREDIT AGREEMENTCredit Agreement • March 21st, 2011 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1, dated as of March 21, 2011 (this “Amendment”), to the Credit Agreement dated as of May 10, 2010 (as the same may be further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (“Borrower”), LANTHEUS MI INTERMEDIATE, INC. (“Lantheus MI”) and LANTHEUS MI REAL ESTATE, LLC (“Lantheus Real Estate” and together with Lantheus MI, the “Guarantors”), Bank of Montreal, as administrative agent (in such capacity, the “Administrative Agent”), Harris N.A., as collateral agent (in such capacity, the “Collateral Agent”), the Lenders from time to time party thereto and the other parties thereto.
AMENDMENT NO. 6 TO THE AGREEMENT CONCERNING CARDIOLITE® AND TECHNELITE® GENERATOR SUPPLY, PRICING AND REBATESThe Agreement • August 14th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
This Amendment No. 6 (“Amendment”) to the Agreement Concerning Cardiolite® and TechneLite® Generator Supply, Pricing and Rebates dated as of February 1, 2008 (as amended, the “Agreement”) is made by and between Lantheus Medical Imaging, Inc., with its principal place of business at 331 Treble Cove Road, North Billerica, Massachusetts 01862 (“Medical Imaging”), and United Pharmacy Partners, Inc., with its principal place of business at 5400 Laurel Springs Parkway, Suite 405, Suwanee, GA 30024 (“UPPI”), and is effective as of April 1, 2012 (the “Amendment Effective Date”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2...License and Supply Agreement • March 29th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 to Amended and Restated Cardiolite® License and Supply Agreement (this “Amendment”) is made effective as of December 27, 2012 (the “Amendment Date”) by and between Lantheus Medical Imaging, Inc. (“LMI”) and Cardinal Health 414, LLC (“Licensee”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. SETTLEMENT AND...Settlement and Release Agreement • March 11th, 2014 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
THIS SETTLEMENT AND RELEASE AGREEMENT (“Settlement Agreement”) is entered into as of November 12, 2013 (the “Effective Date”) by and between BEN VENUE LABORATORIES, INC. (“BVL”), and LANTHEUS MEDICAL IMAGING, INC. (“LMI”). BVL and LMI are collectively referred to as the “Parties” or in the singular as a “Party.”
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 5...Lantheus Medical Imaging, Inc. • March 30th, 2012 • Pharmaceutical preparations • New York
This Amendment No. 5 (“Amendment”) to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates dated as of February 1, 2008 (as amended, the “Agreement”) is made by and between Lantheus Medical Imaging, Inc., with its principal place of business at 331 Treble Cove Road, North Billerica, Massachusetts 01862 (“Medical Imaging”), and United Pharmacy Partners, Inc., with its principal place of business at 5400 Laurel Springs Parkway, Suite 405, Suwanee, GA 30024 (“UPPI”), and is effective as of January 1, 2012 (the “Amendment Effective Date”).
CONSULTING AGREEMENTConsulting Agreement • March 11th, 2014 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (this “Agreement”), effective on the date on which both parties have fully executed the Agreement, is between the Consultant named above and Lantheus Medical Imaging, Inc., with a place of business at 331 Treble Cove Road, N. Billerica, MA 01862 (including its subsidiaries and affiliates, “LMI”).
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • March 11th, 2014 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Massachusetts
This Manufacturing and Supply Agreement (this “Agreement”), dated as of November 12, 2013 (the “Effective Date”), is hereby entered into by and between Lantheus Medical Imaging, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 331 Treble Cove Road, North Billerica, MA 01862 (“LMI”), and Pharmalucence, Inc., a corporation organized and existing under the laws of Delaware with a place of business at 29 Dunham Road, Billerica, MA 01862 (“CMO”). LMI and CMO are referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2...Supply Agreement • March 29th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
This Amendment No. 2 to Amended and Restated Supply Agreement (Thallium and Generators) (this “Amendment”) is made effective as of December 27, 2012 (the “Amendment Date”) by and between Lantheus Medical Imaging, Inc. (“Supplier”) and Cardinal Health 414, LLC (“Cardinal”).
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. EXTENSION TO...Extension • March 8th, 2011 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations
This Extension (the “Extension”) to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates dated as of February 1, 2008 (as amended, the “Agreement”) is made by and between Lantheus Medical Imaging, Inc., with its principal place of business at 331 Treble Cove Road, North Billerica, Massachusetts 01862 (“Medical Imaging”), and United Pharmacy Partners, Inc., with its principal place of business located at 5400 Laurel Springs Parkway, Suite 405, Suwanee, GA 30024 (“UPPI”), and is effective as of January 1, 2011.
CONFIDENTIAL TREATMENT REQUESTED INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “****”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. SECOND...Distribution Agreement • May 15th, 2012 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
This Second Amendment to Distribution Agreement (this “Amendment”) is made by and between Lantheus Medical Imaging, Inc., formerly known as Bristol-Myers Squibb Medical Imaging, Inc. (“LMI”), and Medi-Physics, Inc., doing business as G.E. Healthcare Inc. (“G.E. Healthcare”) (referred to individually as “Party” and collectively as “Parties”), and shall be effective as of January 1, 2012.
LICENSE AND DISTRIBUTION AGREEMENTLicense and Distribution Agreement • March 29th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations
THIS AGREEMENT FOR LICENSE AND DISTRIBUTION OF CARDIOLITE AND NEUROLITE is effective as of the 1st day of January, 2013 by and between Lantheus Medical Imaging, Inc., a Delaware corporation, with its principal place of business at 331 Treble Cove Road, North Billerica, Massachusetts 01862, U.S.A. (formerly known as Bristol-Myers Squibb Medical Imaging, Inc., hereafter referred to as “LMI”), and FUJIFILM RI Pharma Co., Ltd., a corporation of Japan, with its principal place of business at 14-1, Kyobashi 2-chome, Chuo-ku, Tokyo 104-0031 Japan (formerly known as Daiichi Radioisotope Laboratories, Ltd., hereinafter referred to as “FRI”).
FIRST SUPPLEMENTAL INDENTUREFirst Supplemental Indenture • March 16th, 2011 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 14, 2011, among Lantheus Medical Imaging, Inc., a Delaware corporation (or its permitted successor) (the “Issuer”), the Guarantors (as defined in the Indenture referred to herein) and Wilmington Trust FSB, as trustee under the Indenture referred to below (the “Trustee”).
LANTHEUS MI HOLDINGS, INC. 2013 EQUITY INCENTIVE PLAN OPTION GRANT AWARD AGREEMENTJoinder Agreement • May 6th, 2013 • Lantheus Medical Imaging, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT (this “Agreement”) is made as of [ ], 201[ ] (the “Grant Date”), between Lantheus MI Holdings, Inc., a Delaware corporation (the “Company”), and [Name of Grantee] (the “Grantee”). Capitalized terms, unless defined in Section 9 or a prior section of this Agreement, shall have the same meanings as in the Lantheus MI Holdings, Inc. 2013 Equity Incentive Plan (the “Plan”).
